The Lancet · Online First· Tomoki Sakakida, Hiroya Taniguchi, Masako Asayama, Yusuke Suwa, Takaya Shimura, Seiichiro Mitani, Akitaka Makiyama, Hiroyuki Arai, Hiroshi Matsuoka, Mitsuru Yokota, Yoshinao Takano, Kyoko Kato, Hisanobu Oda, Takeshi Kajiwara, Kohei Ogawa, Nobuhiro Shibata, Kentaro Sawada, Takato Yomoda, Toshihiro Kudo, Hiroyuki Okuda, Yuta Okumura, Chihiro Tanaka, Masato Nakamura, Takashi Tsuda, Takahito Kitajima, Hiroshi Tsukuda, Eiji Shinozaki, Mitsuhiro Furuta, Tomomi Kashiwada, Koichi Okuya, Hiroyuki Mushiake, Junichi Hasegawa, Koei Nihei, Takashi Mizushima, Takashi Mine, Takuro Mizukami, Chiho Kudo, Ayako Mishima, Kenta Murotani, Toshiki Masuishi, PRABITAS investigators·· 2 小时前精选AI 评分70
PRABITAS：难治性转移性结直肠癌中，曲氟尿苷替匹嘧啶联合贝伐珠单抗14天方案总生存期非劣于28天方案
[Articles] 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan
AI 导读
PRABITAS试验显示，难治性转移性结直肠癌患者采用曲氟尿苷替匹嘧啶（trifluridine–tipiracil，FTD–TPI）联合贝伐珠单抗（bevacizumab）的14天方案，总生存期非劣于常规28天方案。
推荐理由
该试验将给药周期调整与总生存期非劣效及毒性减少结合评估，为难治性转移性结直肠癌治疗方案简化提供依据。
来源：The Lancet · Online First · thelancet.com